CSF α-synuclein, tau, and amyloid β in Parkinson's disease – Authors' reply

[1]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[2]  J. Wiltfang,et al.  Different CSF β-amyloid processing in Alzheimer’s and Creutzfeldt–Jakob disease , 2011, Journal of Neural Transmission.

[3]  T. Tokuda,et al.  Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.

[4]  Todd Sherer,et al.  Biomarkers in Parkinson's disease: a funder's perspective. , 2010, Biomarkers in medicine.

[5]  W. Schulz-Schaeffer.  The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[6]  Michael L. Kramer,et al.  Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.

[7]  H. Braak,et al.  Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.

[8]  A. Lang,et al.  Interface between tauopathies and synucleinopathies: A tale of two proteins , 2006, Annals of neurology.

[9]  J. Wiltfang,et al.  Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies , 2005, Dementia and Geriatric Cognitive Disorders.

[10]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.